FOLH1 and Familial prostate cancer: Therefore, prospective randomised trials are required to determine the impact of 177Lu-PSMA on survival, toxicities, dosimetry, and to rigorously assess the clinical benefits compared to other treatments for prostate cancer, including chemotherapy, EBRT, and androgen blockade.